SAN DIEGO--(BUSINESS WIRE)--CB Therapeutics, Inc., having achieved the successful biosynthesis of psilocybin, psilocin and other related tryptamine-based compounds, has entered into a Memo of Understanding with the Cleveland Clinic to produce multiple therapeutic tryptamine compounds for clinical trials. These include the production of psilocybin and associated molecules used in combination with psychotherapy for the treatment of depression and addiction, Dimethyltryptamine (DMT) and its analogs for treatment of depression and addiction as well as MDMA analogs for the treatment of PTSD and addiction.
“Psychedelic compounds have the potential to bring significant improvement to the lives of many individuals suffering from mental illness,” says Brian Barnett, M.D. (Center for Behavioral Health) of the Cleveland Clinic. “We look forward to the studies of these compounds and the determination of their safety and efficacy in mental healthcare and treatment as quickly as possible.”
The FDA has already granted psilocybin-assisted psychotherapy a Breakthrough Therapy Designation for major depressive disorder as well as treatment-resistant depression. MDMA-assisted psychotherapy has also been granted this status in trials of Post Traumatic Stress Disorder. This Breakthrough Therapy Designation status allows the FDA to expedite the process of approvals of these compounds. There are also pilot research data indicating that psychedelic compounds may be helpful for other conditions such as opioid use disorder, alcohol use disorder, nicotine use disorder, obsessive compulsive disorder and anxiety.
“It has been our goal, since the inception of the company, to achieve these production milestones and bring these promising compounds to the healthcare community,” states Sher Ali Butt, CEO of CB Therapeutics. “We look forward to being a part of these pivotal studies to seek solutions to some of mankind’s most challenging social and mental healthcare problems.”
About CB Therapeutics
CB Therapeutics, Inc., located in San Diego, California, is a biotechnology company focusing on the innovative production of high value molecules and therapeutic compounds for Neuroscience utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics’ expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms. The CB Therapeutics platform can not only make the active compounds and phytochemicals that occur naturally, but by using enzymatic processes CB Therapeutics has been able to create bio-identical compounds as well as their analogs. These analog compounds may prove to be more effective, targeted and safer for therapeutic purposes.